Glonce

UK weighs killing Palantir's $400M NHS data contract

policyThe Glonce editorsWired🔥48Glonce rating48Impact40Novelty35Relevance62Surprise45Players52Credibility77
UK weighs killing Palantir's $400M NHS data contract

The UK government has a six month window to decide whether to activate a break clause next February and terminate its deal with Palantir, worth more than $400 million, rather than let the contract with the National Health Service run to 2031. Palantir was commissioned in 2023 to build a federated data platform (FDP) that pools health data from across England; the NHS began rolling it out in early 2024. Palantir and the NHS say the FDP is already cutting wait times, shortening hospital stays and improving use of operating theatres. NHS figures show 139 of roughly 200 trusts are currently live with the technology, and 35 of England's 36 integrated care boards (ICBs) are actively using it.

Greater Manchester ICB, which covers about 3 million people, is the sole exception. At a May 2025 meeting the board concluded its homegrown Analytics and Data Science Platform (ADSP) has 'local capability' that 'exceeds anything the FDP currently offers,' with some functions two to three years ahead. Matt Hennessey, chief data and analytics officer at NHS Greater Manchester, argues the ADSP draws on primary care data the FDP does not have, can be reconfigured more easily because it was built in house, and benefits from years of public trust; full adoption of the FDP, he says, 'would be a retrograde step.' Andy Haywood of Health Innovation Manchester says local trusts are not going all in on the FDP even where they are formally listed as users. Palantir disputes this, saying Greater Manchester trusts use the FDP extensively, and Stephen Childs, the company's head of health care partnerships, says thousands of NHS staff use the platform and are on record about its benefits.

The standoff has fed a national political debate. In June, a bipartisan group of UK politicians published a report calling the country's reliance on Palantir an 'unacceptable point of weakness' that hands one foreign vendor excessive leverage, and urged the government to trigger the break clause and pursue domestic alternatives. A separate parliamentary committee made similar arguments the following month, drawing on testimony from Hennessey; its chair, MP Layla Moran, wrote that Palantir 'is evidently not the only show in town.' Both sets of politicians say they are not ideologically motivated, though they also cited a 'clear mismatch with UK values,' a concern sharpened by Palantir's work in warzones and on the US immigration crackdown, cofounder Peter Thiel's past comment that the UK should 'rip the whole [NHS] from the ground and start over,' and a manifesto based on CEO Alex Karp's recent book that one MP called 'the ramblings of a supervillain.'

FDP defenders reject the comparison. Tom Bartlett, an independent IT consultant who formerly ran the national FDP rollout as deputy director of data engineering at NHS England, says the ADSP and FDP 'do completely different things' and that framing the FDP as an analytics tool 'is a complete misrepresentation of the whole goal of the product.' He argues political scrutiny, not technical performance, is driving the debate, and warns that triggering the break clause would set the NHS back: 'there is no alternative. The trusts that were previously using paper would go back to paper.' Hennessey counters that even a technically superior platform fails if clinicians and patients do not trust it enough to use it and supply their data. As of the report, the government's decision remains open, and Greater Manchester's board has said it has not begun its own scheduled review of the FDP decision because public concern has grown rather than eased.

Key facts

  • The UK government has six months to decide whether to trigger a break clause next February and end its NHS contract with Palantir, worth more than $400 million, instead of letting it run to 2031.
  • 139 of roughly 200 NHS trusts and 35 of England's 36 integrated care boards are currently live with Palantir's federated data platform (FDP), but Greater Manchester ICB, covering about 3 million people, has repeatedly refused to adopt it.
  • Greater Manchester's board says its own Analytics and Data Science Platform is functionally superior, up to two to three years ahead on some features, and more trusted by the public than the FDP.
  • A June report from a bipartisan group of UK politicians called reliance on Palantir an 'unacceptable point of weakness,' and a parliamentary committee made similar arguments the following month using testimony from Greater Manchester's data chief.
  • FDP supporters, including a former NHS England rollout lead, argue there is no viable alternative to Palantir at national scale and warn that breaking the contract would push trusts back toward paper records.

Why it matters

The case tests whether a national government will unwind a nine-figure technology contract with a single foreign vendor over trust and sovereignty concerns rather than a documented performance failure. Palantir's NHS deal has become a proxy fight over dependence on US technology suppliers for sensitive public data, a concern the piece notes other European governments are weighing too as relations with the Trump administration cool.

Who it affects

NHS patients across England, whose treatment records flow through whichever platform their trust or care board uses; the roughly 3 million people in Greater Manchester specifically, whose care board has opted out of the national system; NHS trusts and integrated care boards deciding which platform to run; Palantir, whose UK health care business and reputation are at stake; and UK politicians weighing whether to intervene before the February break clause window.

How to use it

There is no product or price to weigh here; the practical read for anyone tracking public sector AI and data contracts is the split outcome so far: 139 of 200 trusts and 35 of 36 ICBs are live on Palantir's FDP, while exactly one region, Greater Manchester, has built and stuck with an in-house alternative, the Analytics and Data Science Platform, developed over roughly a decade.

How solid is it

The account draws on on-the-record statements from named officials on both sides, including NHS Greater Manchester's Matt Hennessey, Palantir UK's Stephen Childs, former NHS England rollout lead Tom Bartlett, and MP Layla Moran, plus NHS adoption figures (139/200 trusts, 35/36 ICBs) and a documented May 2025 board conclusion. Key claims remain disputed rather than independently verified: Palantir says there is scant independent evidence the ADSP has improved care or cut costs, while Andy Haywood disputes Palantir's account of how extensively Greater Manchester trusts actually use the FDP.

Risks and caveats

Several dates in the source are given without a year, including the June politicians' report, the parliamentary committee's follow-up, and the care board's April acknowledgment that it had not begun its own scheduled review, so their exact timing relative to the six month decision window is unclear. The MP who called Palantir's manifesto 'the ramblings of a supervillain' is not named. The debate itself is contested on political grounds: Bartlett argues an 'anti-Palantir campaign' is distorting scrutiny of the contract, while the politicians pushing termination insist their concerns are not ideological despite citing a 'mismatch with UK values.'

“If the break clause got triggered, we'd go backwards, because there is no alternative. The trusts that were previously using paper would go back to paper.”

— Tom Bartlett, independent IT consultant and former deputy director of data engineering at NHS England